



COPY OF PAPERS  
ORIGINALLY FILED

Atty Dkt No. PP00037.201  
2300-0037.04  
PATENT

0300  
#5  
Not Self

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on November 7, 2001

11/7/01      [Signature]  
Date                      Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

COUSENS et al

Serial No.: 09/931,216

Art Unit: Unassigned

Filing Date: August 16, 2001

Examiner: Unassigned

Title:      EXPRESSION FOR USING FUSED GENES PROVIDING FOR  
              PROTEIN PRODUCT

**AMENDMENT TRANSMITTAL LETTER**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Transmitted herewith for filing is an amendment in the above patent application in response to the Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed September 7, 2001.

☐ Petition for Extension of Time enclosed.

☒ No additional fee is required.

☒ Also enclosed: copy of Notice to Comply; Declaration Under 37 CFR §1.825; postcard

No. of Claims After Amendment	Most Claims Previously Paid	Extra Claims	Additional Fee
----------------------------------	--------------------------------	-----------------	----------------

Atty Dkt No. PP00037.201  
2300-0037.04  
PATENT

A. Total Claims	*	-	*	=	*	x	\$18	=	\$*
B. Ind. Claims	*	-	*	=	*	x	\$42	=	*
C. If amended to contain multiple dependent claims, add 280							\$280	=	\$*
D. Total Amendment Fee (Total of A, B & C)								=	*
E. If small entity, 50% reduction of Total Amendment Fee (50% of D)								=	*
F. Total Amendment Fee (D minus E)								=	\$*

— A check for \$ to cover the extension of time fee and extra claims fee is attached.

— Charge \$ to Deposit Account No. 18-1648.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 18-1648.

Respectfully submitted,

Date: 7 Nov 2001

By: Gary R. Fabian  
Gary R. Fabian  
Registration No 33,875  
Attorney for Applicants

ROBINS & PASTERNAK LLP  
90 Middlefield Road, Suite 200  
Menlo Park, CA 94025  
Telephone: 650-325-7812  
Facsimile: 650-325-7823

COPY OF PAPERS  
ORIGINALLY FILED

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/931,216	08/16/2001	Lawrence S. Cousens	PP00037.201

CONFIRMATION NO. 3820

## FORMALITIES LETTER



\*OC000000006529730\*

Lisa E. Alexander  
CHIRON CORPORATION  
Intellectual Property - R440  
P.O. Box 8097  
Emeryville, CA 94662-8097

SEP 2001  
RECEIVED  
PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231

Date Mailed: 09/07/2001

### NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).


- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

**DOCKETED** DSP  
2300-0037.04  
Seq. List due  
11/7/01  
LD 3/7/02

A copy of this notice **MUST** be returned with the reply.

A handwritten signature in dark ink, appearing to be "Paul", is written above a horizontal line.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE